| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/07/2002 | WO2001015673A3 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/07/2002 | WO2001011086A3 Methods of screening for angiogenesis modulators |
| 03/07/2002 | WO2001001974A3 Naaladase inhibitors in anxiety and memory disorders |
| 03/07/2002 | WO2000071571A8 Fap-activated anti-tumor compounds |
| 03/07/2002 | US20020028915 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/07/2002 | US20020028846 Compositions and methods for amelioration of human female sexual dysfunction |
| 03/07/2002 | US20020028838 E.g., 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7 hexahydro-pyrazolo-(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide; mobility impairments, e.g. identified by balance and gait, in the elderly |
| 03/07/2002 | US20020028816 Containing antibiotics such as moxifloxacin; treating infections of Microbacterium species Microbacterium otitidis and Microbacterium alconae |
| 03/07/2002 | US20020028814 Aza compounds, pharmaceutical compositions and methods of use |
| 03/07/2002 | US20020028805 Side effect reduction of tamoxifen, droloxifene, raloxifene, idoxifene, centrochroman, levor, meloxifene, TAT-59, GW 5838, or LY-353381 by administering 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indole-5-ol |
| 03/07/2002 | US20020028799 Using protease and phospodiesterase inhibitor |
| 03/07/2002 | US20020028798 Analgesics, antiinflammatory agents; mixture containing enzyme inhibitor |
| 03/07/2002 | US20020028793 Antilipemic agents, anticholesterol agents, anticoagulants |
| 03/07/2002 | US20020028792 Combinations of bisphosphonates, estrogens and estrogenic agents |
| 03/07/2002 | US20020028790 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity |
| 03/07/2002 | US20020028786 Methods and compositions for enhancing cellular function through protection of tissue components |
| 03/07/2002 | US20020028775 Using mixture of flavonoids, cytochrome inhibitor, sugar, phosphate in carrier |
| 03/07/2002 | US20020028766 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 03/07/2002 | US20020028762 Medicament and method for treating renal disease |
| 03/07/2002 | US20020028761 Neurotherapeutic use of carboxypeptidase inhibitors |
| 03/07/2002 | US20020028235 Dermal penetration enhancer is a safe skin-tolerant ester sunscreen. |
| 03/07/2002 | US20020028227 Use for cosmetic and dermatological indications, reducing and soothing mucosa and skin erythema, inflammation or reaction caused by internal or external factors, wound healing, etc. |
| 03/07/2002 | US20020028203 T cell inhibitory receptor compositions and uses thereof |
| 03/07/2002 | US20020028201 Element A, which is a plastic with a group derived from a carboxy acid (e.g., an acrylate polymer), is hydrogen bonded to an element B (e.g., polyalkylene glycol; coupling physiologically and/or pharmacologically active substances |
| 03/07/2002 | US20020028199 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC) |
| 03/07/2002 | US20020028195 Viruses for the treatment of cellular proliferative disorders |
| 03/07/2002 | US20020028183 Medicaments |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2697205A1 Peptidomimetic protease inhibitors |
| 03/07/2002 | CA2421503A1 Methods and compositions for inhibiting angiogenesis |
| 03/07/2002 | CA2421055A1 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | CA2420867A1 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | CA2420852A1 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 03/07/2002 | CA2420846A1 Treatment of urinary dysfunction |
| 03/07/2002 | CA2420835A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | CA2420804A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 03/07/2002 | CA2420765A1 Anti-angiogenic peptides |
| 03/07/2002 | CA2420696A1 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof |
| 03/07/2002 | CA2420673A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| 03/07/2002 | CA2420591A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | CA2420363A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | CA2420105A1 Human kinases |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2420062A1 Erbb4 antagonists |
| 03/07/2002 | CA2419935A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | CA2419699A1 Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| 03/07/2002 | CA2419623A1 Method for treatment of migraine using pde5 inhibitors |
| 03/07/2002 | CA2419606A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | CA2419483A1 Methods and devices for quantitative analysis of x-ray images |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419342A1 G-protein coupled receptors |
| 03/07/2002 | CA2419256A1 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/07/2002 | CA2419152A1 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 03/06/2002 | EP1184465A2 Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms |
| 03/06/2002 | EP1184454A2 Nav2 channel gene-deficient non-human animals |
| 03/06/2002 | EP1184359A1 Generation of dynamic combinatorial libraries and assessment thereof by deconvolution |
| 03/06/2002 | EP1184037A1 Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 03/06/2002 | EP1184035A2 Use of growth hormone secretagogues for treatment of physical performance decline |
| 03/06/2002 | EP1184034A2 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 03/06/2002 | EP1184031A2 Foaming cosmetic cream for the treatment of fatty skins |
| 03/06/2002 | EP1183534A2 Identification of novel mechanisms of drug resistance |
| 03/06/2002 | EP1183361A1 Gene therapy of pulmonary disease |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183344A2 Adam polynucleotides and polypeptides |
| 03/06/2002 | EP1183333A1 Methods of using rnase p reaction mechanisms of action |
| 03/06/2002 | EP1183330A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN |
| 03/06/2002 | EP1183237A1 Novel antioxidants, preparation methods and uses |
| 03/06/2002 | EP1183229A1 Glucagon antagonists/inverse agonists |
| 03/06/2002 | EP1183228A2 Esters of l-carnitine or alkanoyl l-carnitines |
| 03/06/2002 | EP1183046A1 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 03/06/2002 | EP1183043A2 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183034A1 Modulators of methylation for control of bacterial virulence |
| 03/06/2002 | EP1183031A1 Quinoxaline containing medicaments for post exposure prophylaxis of an hiv infection |
| 03/06/2002 | EP1183026A2 Improved pharmaceutical formulations |
| 03/06/2002 | EP1183024A1 Therapeutic use of melatonin |
| 03/06/2002 | EP1183022A1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183012A1 Novel formulations comprising lipid-regulating agents |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP1182931A1 Stable biocidal compositions |
| 03/06/2002 | EP0912186B1 Progestogen-anti-progestogen regimens |
| 03/06/2002 | EP0883403A4 Method for treating sexual dysfunctions |
| 03/06/2002 | EP0756595B1 Substituted 1,3-oxathiolanes with antiviral properties |
| 03/06/2002 | EP0703784B1 Release and mobilisation of haematopoietic cells |
| 03/06/2002 | EP0613371B1 New combination of formoterol and budesonide |
| 03/06/2002 | CN1339066A Alzheimer's disease secretase |
| 03/06/2002 | CN1338947A Novel mucosal delivery system |
| 03/06/2002 | CN1338946A Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 03/06/2002 | CN1338945A Combination of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 03/06/2002 | CN1338944A Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 03/06/2002 | CN1338942A Self-emulsifying compositions for drugs poorly soluble in water |
| 03/06/2002 | CN1338939A Compositions for the treatment of male erectile dysfunction |
| 03/06/2002 | CN1338937A Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 03/06/2002 | CN1338936A Drug-combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1338456A Benzodiazapine compounds containing imidazole propanamido and its preparing process and application |
| 03/06/2002 | CN1338256A Anticancer compound and its application |
| 03/06/2002 | CN1080125C Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate |
| 03/06/2002 | CN1080119C Pharmaceutical composition contg. proton pump inhibitors |